Shyndec Pharma's Unit Gets Nod to Market Ketamine Hydrochloride

MT Newswires Live

08/08

Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Industrial, received approval from China's National Medical Products Administration to market active pharmaceutical ingredient (API) ketamine hydrochloride, according to a Shanghai bourse disclosure on Friday.

The API is used as an ingredient for anesthetics.

The Chinese pharmaceutical company invested 7.5 million yuan in research and development of the API, the disclosure said.

The company's shares rose over 1% during midday trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557514735"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557514735\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557514735?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 12:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557514735","market":"sh","top_or_hot":-1,"title":"Shyndec Pharma's Unit Gets Nod to Market Ketamine Hydrochloride","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/600420\">Shanghai Shyndec</a> Pharmaceutical's (SHA:600420) unit, Sinopharm Industrial, received approval from China's National Medical Products Administration to market active pharmaceutical ingredient (API) ketamine hydrochloride, according to a Shanghai bourse disclosure on Friday.</p><p>The API is used as an ingredient for anesthetics.</p><p>The Chinese pharmaceutical company invested 7.5 million yuan in research and development of the API, the disclosure said.</p><p>The company's shares rose over 1% during midday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shyndec Pharma's Unit Gets Nod to Market Ketamine Hydrochloride</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShyndec Pharma's Unit Gets Nod to Market Ketamine Hydrochloride\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-08 12:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/600420\">Shanghai Shyndec</a> Pharmaceutical's (SHA:600420) unit, Sinopharm Industrial, received approval from China's National Medical Products Administration to market active pharmaceutical ingredient (API) ketamine hydrochloride, according to a Shanghai bourse disclosure on Friday.</p><p>The API is used as an ingredient for anesthetics.</p><p>The Chinese pharmaceutical company invested 7.5 million yuan in research and development of the API, the disclosure said.</p><p>The company's shares rose over 1% during midday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0132","symbol_name":"高送转概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2557514735","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557514735","pubTimestamp":1754627130,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Shyndec Pharmaceutical's  unit, Sinopharm Industrial, received approval from China's National Medical Products Administration to market active pharmaceutical ingredient  ketamine hydrochloride, according to a Shanghai bourse disclosure on Friday.The API is used as an ingredient for anesthetics.The Chinese pharmaceutical company invested 7.5 million yuan in research and development of the API, the disclosure said.The company's shares rose over 1% during midday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600420":"国药现代","BK0132":"高送转概念","API.AU":"Australian Pharma Industries","OTX.SI":"迈怡汇有限公司","BK7103":"保健护理产品经销商","BK0020":"浦东新区","BK4023":"应用软件","BK6100":"保健护理服务","BK4535":"淡马锡持仓","API":"声网","BK0082":"国资改革","BK0010":"央企","BK4503":"景林资产持仓","BK6520":"工商业服务概念","BK0239":"医药制造","BK4551":"寇图资本持仓"},"translate_title":"Shyndec Pharma的子公司获准销售盐酸氯胺酮","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600420":0.9,"API":1,"API.AU":1,"OTX.SI":0.9},"content_text":"Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Industrial, received approval from China's National Medical Products Administration to market active pharmaceutical ingredient (API) ketamine hydrochloride, according to a Shanghai bourse disclosure on Friday.The API is used as an ingredient for anesthetics.The Chinese pharmaceutical company invested 7.5 million yuan in research and development of the API, the disclosure said.The company's shares rose over 1% during midday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}